Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis

Assis, Joana; Pereira, Carina; Nogueira, Augusto; Pereira, Deolinda; Carreira, Rafael; Medeiros, Rui

doi:10.1016/j.ctrv.2017.10.001

Cited by 16 publications

(15 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interindividual variation in platinum-drug response might be a major determinant for OC. This is suggested from the wide variability in the PFI and its direct association with a platinum response, as well as the finding that intrinsic resistance to these compounds, occur in up to a fifth of OC patients [106][107][108][109]. Mechanisms involved in platinum resistance are likely to be multifactorial although seems to be greatly determined by the platinum detoxification pathway and DNA damage repair ability [54,108,[110][111][112][113].…”

Section: Pharmacogenomics For Future Predictive Marker Definitionmentioning

confidence: 99%

“…Taxanes are microtubule-stabilizing drugs, inducing cell cycle arrest and activating proapoptotic signaling. The cellular toxicity to taxanes is controlled by the action of multiple mediators, namely those involved in transport (i.e., ABCB1, ABCC1, and ABCC2), metabolism, and metabolism-associated proteins (cytochrome P450s and nuclear receptors), as well as pharmacodynamics (i.e., TP53 and CDKN1A), which appear to play a role in taxane efficacy [54,108,[114][115][116]. However, to date, no reliable biomarker or signature exists to predict the sensitivity or resistance to paclitaxel.…”

Section: Pharmacogenomics For Future Predictive Marker Definitionmentioning

confidence: 99%

See 1 more Smart Citation

Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application

Assis¹,

Pereira²,

Nogueira³

et al. 2018

Ovarian Cancer - From Pathogenesis to Treatment

Self Cite

View full text Add to dashboard Cite

Over the previous two decades, there has been a shift in the ovarian cancer paradigm to consider it as a multiplicity of disease types rather than a single disease, requiring specialized medical management from molecular diagnosis through to treatment. Despite the achieved improvements in diagnosis, surgery, and systemic treatment, ovarian cancer remains the leading cause of death from gynecological tumors in western countries. The study of ovarian cancer at a molecular level could reveal potential biomarkers of disease diagnosis and progression, as well as possible therapeutic targets in areas such as angiogenesis and homologous recombination deficiencies. Although this area of research is proving invaluable concerning newer therapeutic approaches, platinum-based chemotherapy continues to be the core of the first-line treatment. Genomic screening focusing on the identification of prognostic and predictive markers is considered one of the leading areas for future ovarian cancer research.

show abstract

Section: Pharmacogenomics For Future Predictive Marker Definitionmentioning

confidence: 99%

Section: Pharmacogenomics For Future Predictive Marker Definitionmentioning

confidence: 99%

Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application

Assis¹,

Pereira²,

Nogueira³

et al. 2018

Ovarian Cancer - From Pathogenesis to Treatment

Self Cite

View full text Add to dashboard Cite

show abstract

“…Due to a paucity of effective screening modalities, most patients are diagnosed at advanced stages (5)(6)(7). Clinically, the most widely adopted standard treatment regimen for advanced ovarian cancer includes surgery, target therapy, and chemotherapy (8)(9)(10). Tumor metastasis and resistance to apoptosis contributes to a poor survival rate in clinical ovarian cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway

Xiaomeng

et al. 2020

Braz J Med Biol Res

View full text Add to dashboard Cite

In this study, we aimed to analyze the anti-cancer effects of b-elemene combined with paclitaxel for ovarian cancer. RT-qPCR, MTT assay, western blot, flow cytometry, and immunohistochemistry were used to analyze in vitro and in vivo anti-cancer effects of combined treatment of b-elemene and paclitaxel. The in vitro results showed that b-elemene+paclitaxel treatment markedly inhibited ovarian cancer cell growth, migration, and invasion compared to either paclitaxel or b-elemene treatment alone. Results demonstrated that b-elemene+paclitaxel induced apoptosis of SKOV3 cells, down-regulated anti-apoptotic Bcl-2 and Bcl-xl gene expression and up-regulated pro-apoptotic P53 and Apaf1 gene expression in SKOV3 cells. Administration of b-elemene+paclitaxel arrested SKOV3 cell cycle at S phase and down-regulated CDK1, cyclin-B1, and P27 gene expression and apoptotic-related resistant gene expression of MDR1, LRP, and TS in SKOV3 cells. In vivo experiments showed that treatment with b-elemene+paclitaxel significantly inhibited ovarian tumor growth and prolonged the overall survival of SKOV3bearing mice. In addition, the treatment inhibited phosphorylated STAT3 and NF-kB expression in vitro and in vivo. Furthermore, it inhibited migration and invasion through down-regulation of the STAT-NF-kB signaling pathway in SKOV3 cells. In conclusion, the data suggested that b-elemene+paclitaxel can inhibit ovarian cancer growth via down-regulation of the STAT3-NF-kB signaling pathway, which may be a potential therapeutic strategy for ovarian cancer therapy.

show abstract

“…Aggregation of specific genetic alterations, particularly Single Nucleotide Polymorphisms (SNPs) contribute to OC predisposition 14 . SNPs investigated in the present study include genes like DNMT3A, PIK3CA, FGFR2, GSTP1, ERCC5, AKT1, CASC16, CYP19A1, BCL2, andERCC1.SNPs of these genes have been found in association with cancers of ovary, breast, stomach and lung among different populations, globally [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] . Recently, reported association of XRCC1 (rs25487), HoGG1 (rs1052133), DNAH11(rs2285947) and LRFN2(rs2494938) gene variants with OC provided an insight that genetic variants provide increased risk in the present populations 9,31 .…”

mentioning

confidence: 99%

“…Besides these two reports, no genetic data is available on OC from the J&K region. In order to extend screening, more genetic variants in the J&K population, in-house cancer SNP panel was designed to screen the OC patients that comprises of eleven SNPs of ten genes (DNMT3A 17 , PIK3CA 21,22 , FGFR2 21,22 , GSTP1 21,22 , ERCC5 [18][19][20] , AKT1 16 , CASC16 15 , CYP19A1, BCL2 15,23,24 , ERCC1 [25][26][27][28][29][30] ); and population based association study was conducted to assess the genetic predisposition of cancer susceptibility variants with OC.…”

mentioning

confidence: 99%

MassArray analysis of genomic susceptibility variants in ovarian cancer

Verma

Sharma²,

Sharma³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Ovarian cancer (OC), a multifaceted and genetically heterogeneous malignancy is one of the most common cancers among women. The aim of the study is to unravel the genetic factors associated with OC and the extent of genetic heterogeneity in the populations of Jammu and Kashmir (J&K).Using the high throughput Agena MassARRAY platform, present case control study was designed which comprises 200 histopathological confirmed OC patients and 400 age and ethnicity matched healthy controls to ascertain the association of previously reported eleven single nucleotide polymorphisms (SNPs) spread over ten genes (DNMT3A, PIK3CA, FGFR2, GSTP1, ERCC5, AKT1, CASC16, CYP19A1, BCL2 and ERCC1) within the OC population of Jammu and Kashmir, India. The association of each variant was estimated using logistic regression analyses. Out of the 11 SNPs the odds ratio observed for three SNPs; rs2699887 was (1.72 at 95% CI: 1.19–2.48, p = 0.004), rs1695 was (1.87 at 95% CI: 1.28–2.71, p = 0.001), and rs2298881 was (0.66 at 95% CI: 0.46–0.96, p = 0.03) were found significantly associated with the OC after correction with confounding factors i.e. age & BMI. Furthermore, the estimation of interactive analyses was performed and odds ratio observed was 2.44 (1.72–3.47), p value < 0. 001 suggests that there was a strong existence of interplay between the selected genetic variants in OC, which demonstrate that interactive analysis highlights the role of gene–gene interaction that provides an insight among multiple little effects of various polymorphisms in OC.

show abstract

Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis

Cited by 16 publications

References 182 publications

Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application

Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application

Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway

MassArray analysis of genomic susceptibility variants in ovarian cancer

Contact Info

Product

Resources

About